Medtrack 2013 Royalties Report

Analysis of Average Royalty Rates in Pharma by Phase and Therapy Area

December 06, 2013

<p>Medtrack has published a new report analyzing royalty rates in Pharma by both <strong>Phase</strong> and <strong>Therapy Area</strong>. This report can help maximize royalty rate opportunities in the Biotech and Pharma licensing space. Royalty payments are an essential component of most pharmaceutical deals. Along with upfront payments and milestones, companies are rewarded for surpassing certain developmental hurdles. A properly structured deal will achieve a balance among these financial payment types. This begs the question of what is the proper royalty rate to be paid to the product owner or originator. In order to address this, an analysis of historical royalty rates in the pharmaceutical sector was assembled using Medtrack&rsquo;s Royalty Analyzer. About Medtrack<br />Medtrack, a leading provider of pharmaceutical and commercial intelligence information, follows nearly 32,000 pharmaceutical, biotechnology and medical device companies, 124,000 drugs (including generics) spanning 2,100 indications, and 105,000 deals including partnerships, mergers, acquisitions, venture financings, public offerings and private placements for both private and public companies worldwide.</p>